President Donald Trump, flanked by General Gustave Perna, head of operations of Operation Warp Speed, and Moncef Slaoui, the program's chief scientist, on Sep 18, 2020 at the White House. WASHINGTON: President Donald Trump's announcement in May of plans to develop a COVID-19 vaccine by year's end is near realisation - despite a setback among one of the six candidates that the US supported.
It brought together the scientific expertise of the Department of Health and Human Services and military logistics experts. The operation relied on six projects, two each for three kinds of vaccine technology so as to spread out the risk of one or more failing.Advertisement Then questions emerged over good efficacy results announced by the developers, due to a dosage error. The team announced Thursday it needed to do another study.The US can probably afford to go without the AstraZeneca candidate as it awaits new data, as millions of Americans will be vaccinated with Pfizer or Moderna shots by December 31 if the FDA gives the green light.
"The force of investment has had an extremely important accelerating effect," Loic Chabanier of the consulting firm EY told AFP. The US ordered 100 million doses from the company, with bill payable even if the vaccine had turned out to be a dud.But experts generally avoid giving any credit to Trump, whose handling of the pandemic is criticized as disastrous, relying solely on vaccines to end the pandemic and failing to push public health measures that could have saved tens of thousands of lives.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.